REDES Study: Mepolizumab Is Effective in Patients With Severe Asthma and Comorbid Nasal Polyps

More than 90% of patients with severe asthma and the eosinophilic phenotype have comorbid diseases, with chronic rhinosinusitis with nasal polyps (CRSwNP) being one of the most common. The REDES study evaluated the effectiveness and safety of mepolizumab in patients with severe asthma and comorbid CRSwNP. The study population consisted of 318 severe asthma patients, of whom 147 had comorbid CRSwNP. The study found that mepolizumab treatment resulted in a significant reduction in exacerbations and oral corticosteroid use in both groups. Additionally, patients with CRSwNP showed improved asthma control and lung function. The study highlights the importance of a multidisciplinary approach involving respiratory physicians, allergists, and ENT specialists in the diagnosis and treatment of severe asthma with comorbid nasal polyps. The results of the study are consistent with previous clinical trials and real-world studies, suggesting that patients with severe asthma and comorbid nasal polyps respond well to mepolizumab treatment.